ALK2 inhibitors and methods for inhibiting BMP signaling
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
A 1 is NR 4a or CR 4b R 5 ;
B 1 is N or CR 2 ;
Z 1 is N or CR 3 ;
R 1 is selected from cycloalkyl, aryl, heteroaryl, and heterocyclyl;
R 2 is H, CN, NO 2 , alkyl, or amino;
R 3 is selected from H, CN, NO 2 , alkyl, alkoxy, heterocyclyloxy, heteroaryloxy, aryloxy, cycloalkyloxy, carbonyl, amino, amido, sulfonyl, sulfonamido, cycloalkyl, aryl, heterocyclyl, and heteroaryl;
R 4a is selected from alkyl, alkenyl, alkynyl, carbonyl, O − , alkoxycarbonyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl;
R 4b is selected from halo, CN, NO 2 , hydroxy, alkyl, alkenyl, alkynyl, alkoxy, heterocyclyloxy, heteroaryloxy, aryloxy, cycloalkyloxy, amino, amido, carbonyl, alkoxycarbonyl, carboxy, sulfonyl, sulfonamido, thio, cycloalkyl, aryl, heterocyclyl, and heteroaryl;
R 5 is selected from H, halo, hydroxy and alkyl, or R 4b and R 5 together with A 1 form a ring selected from cycloalkyl and heterocyclyl;
each R 6 is independently selected from H, halo, CN, NO 2 , hydroxy, alkyl, alkenyl, alkynyl, alkoxy, heterocyclyloxy, heteroaryloxy, aryloxy, cycloalkyloxy, amino, amido, carbonyl, alkoxycarbonyl, carboxy, sulfonyl, sulfonamido, thio, cycloalkyl, aryl, heterocyclyl, and heteroaryl and oxo;
n is 0 or 1;
m is 0 or 1; and
x is 0, 1, 2, 3, or 4.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
A 1 is NR 4a or CR 4b R 5 ;
B 1 is N or CR 2 ;
Z 1 is N or CR 3 ;
R 1 is selected from aryl, heteroaryl, and heterocyclyl;
R 2 is H or amino;
R 3 is H or heterocyclyloxy;
R 4a is selected from alkyl, O − , aryl, heterocyclyl, and heteroaryl;
R 4b is selected from alkyl, alkoxy, amino, aryl, heterocyclyl, and heteroaryl;
R 5 is selected from H and alkyl, or
R 4b and R 5 together with A 1 form a ring selected from cycloalkyl and heterocyclyl;
each R 6 is independently selected from H, halo, alkyl and oxo;
n is 0 or 1;
m is 0 or 1; and
x is 0, 1, 2, 3, or 4.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from H, aryl, 5-6 membered heteroaryl,
wherein:
each E is independently selected from N and CR 1d ;
each G is independently selected from N and CR 1e ;
K 1 is N or CH;
K 2 is NH or S;
M is N or CR 1a ;
R 1a is selected from H, halo, alkyl, haloalkyl, and amido;
R 1b is selected from H, halo, CN, alkyl, haloalkyl, hydroxy, alkoxy, and haloalkoxy;
R 1c is selected from H, halo, CN, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino and amido, or
R 1b and R 1c together with the carbon atoms to which they are attached form a heterocyclyl;
R 1d is selected from H, CN, alkyl, haloalkyl, hydroxy, amido and sulfonamido;
R 1e is selected from H, alkyl and amino; and
R 1g is H or halo.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R 4a is selected from alkyl, O, heterocyclyl, and heteroaryl;
R 4b is selected from alkyl, alkoxy, amino, amido, heterocyclyl, and heteroaryl;
R 5 is selected from H and alkyl, or
R 4b and R 5 together with A 1 form a heterocyclyl; and
each R 6 is independently selected from H, halo, and alkyl; and
x is 0 or 1.
5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from H, aryl, 5-6 membered heteroaryl,
wherein:
each E is independently selected from N and CR 1d ;
each G is independently selected from N and CR 1e ;
K 1 is N or CH;
K 2 is NH or S;
M is CR 1a ;
R 1a is selected from H and amido;
R 1b is selected from H, halo, alkyl, and alkoxy;
R 1c is selected from H, alkyl, and alkoxy, or
R 1b and R 1c together with the carbon atoms to which they are attached form a heterocyclyl;
R 1d is selected from H, alkyl, hydroxy, amido and sulfonamido;
R 1e is selected from H, alkyl and amino;
R 1f is H; and
R 1g is H.
6. A compound having a formula selected from:
or a pharmaceutically acceptable salt thereof.
7. A compound having a formula selected from:
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
9. A method of treating a subject having anemia, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the anemia is iron deficiency anemia or anemia of inflammation.
11. The method of claim 9 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
12. A method of treating a subject having fibrodysplasia ossificans progressiva, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
13. The method of claim 12 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.